Marinus Pharmaceuticals

$1.10
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.03 (-2.70%) Today
+$0.02 (1.85%) As of 5:37 PM EDT after-hours

Why Robinhood?

You can buy or sell MRNS and other stocks, options, ETFs, and crypto commission-free!

About MRNS

Marinus Pharmaceuticals, Inc. Common Stock, also called Marinus Pharmaceuticals, is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Read More Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA.

Employees
28
Headquarters
Radnor, Pennsylvania
Founded
2003
Market Cap
56.79M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
550.39K
High Today
$1.16
Low Today
$1.07
Open Price
$1.13
Volume
713.87K
52 Week High
$10.54
52 Week Low
$0.77

Collections

MRNS Earnings

-$0.27
-$0.23
-$0.19
-$0.15
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
Actual
Expected Oct 29, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.